Respiratory Medicine
Volume 104, Issue 8 , Pages 1081-1091 , August 2010

Statins in community acquired pneumonia: Evidence from experimental and clinical studies

  • James D. Chalmers

      Affiliations

    • University of Edinburgh, Edinburgh, UK
    • Corresponding Author InformationCorresponding author at: Centre for Inflammation Research, Queens Medical Research Institute, 51 Old Dalkeith Road, Edinburgh EH16 4TJ, UK. Tel./fax: +44 1312421908.
    • ,
  • Philip M. Short

      Affiliations

    • Ninewells Hospital, Dundee, UK
    • ,
  • Pallavi Mandal

      Affiliations

    • Royal Infirmary of Edinburgh, Edinburgh, UK
    • ,
  • Ahsan R. Akram

      Affiliations

    • Royal Infirmary of Edinburgh, Edinburgh, UK
    • ,
  • Adam T. Hill

      Affiliations

    • Royal Infirmary of Edinburgh, Edinburgh, UK

Received 13 December 2009 ,Accepted 7 April 2010.

References 

  1. Trotter CL, Stuart JM, George R, Miller E. Increasing hospital admissions for pneumonia. England. Emerg Infect Dis. 2008;14(5):727–733
  2. Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patients Outcomes Research Team cohort study. Arch Intern Med. 2002;162(9):1059–1064
  3. Lim WS, M van der Eerden M, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–382
  4. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–250
  5. Chalmers JD, Singanayagam A, Hill AT. Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia. Thorax. 2008;63(8):698–702
  6. Niederman MS, McCombs JI, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20:820–837
  7. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167(15):1655–1663
  8. Group Scandinavian Simvastatin Survival Study . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;19;344(8934):1383–1389
  9. Pfeffer MA, Sacks FM, Moyé LA, Brown L, Rouleau JL, Hartley LH, et al. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol. 1995;28;76(9):98C–106C
  10. Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;5;339(19):1349–1357
  11. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333(2):1301–1307
  12. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–2346
  13. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2004;117:596–606
  14. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Air Force/Texas coronary atherosclerosis prevention study investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;28;344(26):1959–1965
  15. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996;348:1079–1082
  16. Correia LC, Sposito AC, Passos LC, Lima JC, Braga JC, Rocha MS, et al. Anti-inflammatory effect of atorvastatin (80mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol. 2003;92:298–301
  17. Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol. 2006;28;109(1):7–15
  18. Ross R. Atherosclerosis- an inflammatory disease. N Engl J Med. 1999;14;340(2):115–126
  19. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839–844
  20. Albert MA, Danielson E, Rifai N, Ridker PM. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation. JAMA. 2001;286:64–70
  21. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477–1482
  22. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29–38
  23. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28
  24. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399–1402
  25. Mach F. Statins as novel immunomodulators: from cell to potential clinical benefit. Thromb Haemost. 2003;90:607–610
  26. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis. 2007;7(5):358–368
  27. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37–44
  28. Paumelle R, Staels B. Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc Med. 2008;18(3):73–78
  29. Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med. 2008;358:716–727
  30. Shyamsundar M, McKeown ST, O’Kane CM, Craig TR, Brown V, Thickett DR, et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med. 2009;179(12):1107–1114
  31. Gipson TS, Bless NM, Shanley TP, Crouch LD, Bleavins MR, Younkin EM, et al. Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury. J Immunol. 1999;162(6):3653–3662
  32. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1334–1349
  33. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, Van Loo G, et al. Identification of oxidative stress and toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;18;133(2):235–249
  34. Jacobson JR, Dudek SM, Birukov KG, Ye SQ, Grigoryev DN, Girgis RE, et al. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol. 2004;30:662–670
  35. Koh KK, Ahn JY, Jin DK, Han SH, Kim HS, Choi IS, et al. Comparative effects of statin and fibrate on nitric oxide bioactivitiy and matrix metalloproteinase in hyperlipidemia. Int J Cardiol. 2004;97(2):239–244
  36. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, et al. HMG coA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998;18(11):1671–1678
  37. Yao HW, Mao LG, Zhu JP. Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury. Clin Exp Pharmacol Physiol. 2006;33(9):793–797
  38. Pirat A, Zeyneloglu P, Aldemir D, Yucel M, Ozen O, Candan S, et al. Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats. Anesth Analg. 2006;102(1):225–232
  39. Fessler MB, Young SK, Jeyaseelan S, Lieber JG, Arndt PG, Nick JA, et al. A role for hydroxy-methylglutaryl coenzyme A reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med. 2005;171:606–615
  40. Erkkila L, Jauhiainen M, Laitinen K, Haasio K, Tiirola T, Saikku P, et al. Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumonia infection in mice. Antimicrob Agents Chemother. 2005;49(9):3959–3962
  41. Tiirola T, Jauhiainen M, Erkkila L, Bloigu A, Leinonen M, Haasio K, et al. Effect of Pravastatin treatment on Chlamydia pneumonia infection, inflammation and serum lipids in NIH/S mice. Int J Antimicob Agents. 2007;29(6):741–742
  42. Chello M, Anselmi A, Spadaccio C, Patti G, Goffredo C, Di Sciascio G, et al. Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Ann Thorac Surg. 2007;83(4):1374–1380
  43. Namazi MR. Decreasing the expression of LFA-1 and ICAM-1 as well as hindering their interaction as the major mechanism for statin-induced neutrophil dysfunction. Ann Thorac Surg. 2007;84(6):2137–2138
  44. Stenvinkel P, Rodriguez-Ayala E, Massy ZA, Qureshi AR, Barany P, Fellstrom B, et al. Statin treatment and diabetes affect myeloperoxidase activity in maintanence haemodialysis patients. Clin J Am Soc Nephrol. 2006;1(2):281–287
  45. Guasti L, Marino F, Cosentino M, Maio RC, Rasini E, Ferrari M, et al. Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1 year follow-up. Eur Heart J. 2008;29(9):1118–1126
  46. Maher BM, Dhonnchu TN, Burke JP, Soo A, Wood AE, Watson RW. Statins alter neutrophil migration by modulating cellular Rho activity- a potential mechanism for statin-mediated pleotropic effects?. J Leukoc Biol. 2009;85(1):186–193
  47. Durant R, Klouche K, Delbosc S, Morena M, Arnigues L, Beraud JJ, et al. Superoxide anion overproduction in sepsis: effects of vitamin e and simvastatin. Shock. 2004;22(1):34–39
  48. Choi G, Hofstra JJ, Roelofs JJ, Rijneveld AW, Bresser P, Van der Zee JS, et al. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during streptococcus pneumoniae pneumonia in rats. Crit Care Med. 2008;36:204–210
  49. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2000;161:454–462
  50. Rijneveld AW, Weijer S, Bresser P, Florquin S, Vlasuk GP, Rote WE, et al. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med. 2006;34:1725–1730
  51. Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol. 2000;22:401–404
  52. Bernard GR, Vincent JL, Laterre PF, LaRosa P, Dhainaut JDF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;8;344(10):699–709
  53. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:247–251
  54. Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31:2442–2449
  55. Bourcier T, Libby P. HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:556–562
  56. Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, et al. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinol. 2003;14:575–585
  57. Laterre PF. Clinical trials in severe sepsis with drotrecogin Alfa (activated). Crit Care. 2007;11(Suppl. 5):S5
  58. Vincent JL, Zhang H, Szabo C, Preiser JC. Effects of nitric oxide in septic shock. Am J Respir Crit Care Med. 2000;161:1781–1785
  59. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109–142
  60. Vo PA, Lad B, Tomlinson JA, Francis S, Ahluwalia A. Autoregulatory role of endothelium-derived nitric oxide (NO) on lipopolysaccharide-induced vascular inducible NO synthase expression and function. J Biol Chem. 2005;280:7236–7243
  61. Gardiner SM, Kemp PA, March JE, Bennett T. Temporal differences between the involvement of angiotensin II and endothelin in the cardiovascular responses to endotoxaemia in conscious rats. Br J Pharmacol. 1996;119:1619–1627
  62. McGown CC, Brookes ZLS. Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide. Br J Anaesth. 2007;98:163–175
  63. Wei XQ, Charles IG, Smith A, Ure J, Feng GJ, Huang FP, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature. 1995;375:408–411
  64. Grover R, Zaccardelli D, Colice G, Guntupalli K, Watson D, Vincent JL. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med. 1999;27:913–922
  65. Yamashita T, Kawashima S, Ohashi Y, Ozaki M, Ueyama T, Ishida T, et al. Resistance to endotoxin shock in transgenic mice overexpressing endothelial nitric oxide synthase. Circulation. 2000;101:931–937
  66. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129–1135
  67. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Proc Natl Acad Sci USA. 1998;95:8880–8885
  68. Alvarez de Sotomayor M, Vega S, Mingorance C, Mahuenda E, Herrera MD. Effects of HMG-CoA reductase inhibition by simvastatin on vascular dysfunction induced by lipopolysaccharide in rats. Pharmacology. 2008;82(2):89–96
  69. Pleiner J, Schaller G, Mittermayer F, Zorn S, Marsik C, Polterauer S, et al. Simvastatin prevents vascular hyporeactivity during inflammation. Circulation. 2004;110:3349–3354
  70. Lucas R, Verin AD, Black SM, Catravas JD. Regulators of endothelial and epithelial barrier integrity and function in acute lung injury. Biochem Pharmacol. 2009;17(12):1763–1772
  71. Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JG. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol. 2005;288(6):L1026–L1032
  72. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory tract infections and risk of first time acute myocardial infarction. Lancet. 1998;351:1467–1471
  73. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611–2618
  74. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45:158–165
  75. Ramirez J, Aliberti S, Mirsaeidi M, Peyrani P, Filardo G, Amir A, et al. Acute myocardial infarction in hospitalized patients with community acquired pneumonia. Clin Infect Dis. 2008;47:182–187
  76. Merx MW, Weber C. Sepsis and the heart. Circulation. 2007;116(7):793–802
  77. Jafri SM, Lavine S, Field BE, Bahorozian MT, Carlson RW. Left ventricular diastolic function in sepsis. Crit Care Med. 1990;18:709–714
  78. Poelaert J, Declerck C, Vogelaers D, Colardyn F, Visser CA. Left ventricular systolic and diastolic function in septic shock. Intens Care Med. 1997;23:553–560
  79. Ren J, Ren BH, Sharma AC. Sepsis-induced depressed contractile function of isolated ventricular myocytes is due to altered calcium transient properties. Shock. 2002;18:285–288
  80. McDonough KH, Smith T, Patel K, Quinn M. Myocardial dysfunction in the septic rat heart: role of nitric oxide. Shock. 1998;10:371–376
  81. Merx MW, Liehn EA, Graf J, Van de Sandt A, Schaltenbrand M, Schrader J, et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation. 2005;112(1):117–124
  82. Van de Garde EM, Hak E, Souverein PC, Hoes AW, Van Den Bosch JM, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax. 2006;61(11):957–961
  83. Schlienger RG, Fedson DS, Jick SS, Meier CR. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy. 2007;27(3):325–332
  84. Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJ, Gibson JE. Risk of community-acquired pneumonia and the use of statins, ace-inhibitors and gastric acid suppressants. A population based case-control study. Pharmacoepidemiol Drug Saf. 2009;18(4):269–275
  85. Dublin S, Jackson ML, Nelson JC, Weiss NS, Larson EB, Jackson LA. Statin use and risk of community acquired pneumonia in older people: population based case control study. BMJ. 2009;16:338;b2137
  86. Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJ, McKeever TM. The impact of statins, ACE inhibitos and gastric acid suppressants on pneumonia mortality in a UK general practice cohort. Pharmacoepidemio Drug Saf. 2009;18(8):697–703
  87. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004;17;110(7):880–885
  88. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res. 2005;25(6):82
  89. Mortensen EM, Pugh MJ, Copeland LA, Restrepo MI, Cornell JE, Anzueto A, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J. 2008;31(3):611–617
  90. Mortensen EM, Restrepo MI, Copeland LA, Pugh JA, Anzueto A, Cornell JE, et al. Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy. 2007;27(12):1619–1626
  91. Majumdar SR, McAllister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 2006;333:999
  92. Eurich DT, Marrie TJ, Johnstone J, Majumdar SR. Mortality reduction with influenza vaccine in patients with pneumonia outside “flu” season: pleiotropic benefits or residual confounding?. Am J Respir Crit Care Med. 2008;1;178(5):527–533
  93. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and Outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996;275:134–141
  94. Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med. 2008;121(11):1002–1007e1
  95. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sorensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med. 2008;27;168(19):2081–2087
  96. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006;367(9508):413–418
  97. Fernandez R, De Pedro BJ, Artigas A. Statin Therapy prior to ICU admission: protection against infection or a severity marker?. Intens Care Med. 2006;32(1):160–164
  98. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin Therapy is associated with fewer deaths in patients with bacteraemia. Intens Care Med. 2006;32(1):75–79
  99. Yang KC, Chien JY, Tseng WK. Statins do not improve short term survival in an oriental population with sepsis. Am J Emerg Med. 2007;25(5):494–501
  100. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis. 2001;15;33(8):1352–1357
  101. Schmidt H, Hennen R, Keller A, Russ M, Muller-Werdan U, Werdan K, et al. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intens Care Med. 2006;32(8):1248–1251
  102. Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, Sorensen HT, Schonheyder HC, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med. 2006;34(4):1080–1086
  103. Novack V, Eisinger M, Frenkel A, Terblanche M, Adhikari NK, Douvdevani A, et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intens Care Med. 2009;35(7):1255–1260

PII: S0954-6111(10)00158-7

doi: 10.1016/j.rmed.2010.04.005

Respiratory Medicine
Volume 104, Issue 8 , Pages 1081-1091 , August 2010

Article Tools

* Image Usage & Resolution